Applied Filters
Fed Circuit reverses Novartis’ drug patent win
The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Teva settles patent dispute with Aurobindo
Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Novartis, Dana-Farber seek to bar generic leukaemia drug
Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.
Senators urge USPTO to curb ‘patent thicket’ abuse
A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Pfizer sues MSN Labs over Xeljanz generic
Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.
California judge approves BMS $10.8m settlement
A judge at the US District Court for the Northern District of California has granted a motion for preliminary approval of a $10.8 million settlement in an antitrust suit.
BMS says Hengrui’s Abraxane infringes
A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
AstraZeneca says Mylan, Kindeva infringe another Symbicort patent
AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.
BioMarin, MSD sue Aurobindo over rare disease drug
BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.
Aetna gets antitrust suit moved back to state court
American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.
